Información del artículo
Resumen
Introducción
Desde la publicación de la primera edición de la Guía en 2013, se ha generado mucha información en torno al tratamiento de la colitis ulcerosa, y se han introducido nuevos fármacos y protocolos de actuación. La práctica clínica ha variado substancialmente, lo que justifica nuevas aproximaciones y una revisión exhaustiva, así como la actualización de la evidencia.
Material y métodosSe utiliza nuevamente metodología GRADE, apoyados en una herramienta electrónica (https://gradepro.org). Los escenarios clínicos son los mismos que en la versión previa (inducción y mantenimiento en brote grave y en brote leve-moderado), así como las variables y su evaluación. En la guía actualizada, en relación a la versión previa, se eliminan tres preguntas, se añaden 14 y se mantienen 30, con un total de 44 preguntas clínicas. Tras una exhaustiva revisión de la evidencia, se actualizan las recomendaciones.
ResultadosDe las 44 preguntas analizadas, en dos de ellas no se ha podido establecer ninguna recomendación por muy baja calidad de la evidencia, mientras que en las 42 restantes, basados en diferentes grados de calidad de evidencia, se ha formulado una recomendación de acuerdo con el sistema GRADE. En 25 de estas preguntas la recomendación final es fuerte a favor; en seis, fuerte en contra; mientras que en siete es débil a favor, y en cuatro débil en contra. Siguiendo los escenarios y las recomendaciones, se proponen seis algoritmos como guía sencilla en la toma de decisiones prácticas.
ConclusionesEsta actualización de la guía previa publicada en 2013 intenta dar respuesta basada en la metodología GRADE a las diferentes preguntas que nos hacemos diariamente a la hora de decidir el tratamiento más adecuado de nuestros pacientes con colitis ulcerosa en los diferentes escenarios clínicos.
Palabras clave:
Colitis ulcerosa
Tratamiento
Salicilatos
Corticoides
Inmunosupresores
Biológicos
GRADE
Abstract
Introduction
Since the first edition of the Guidelines was published in 2013, much information has been generated around the treatment of ulcerative colitis, and new drugs and action protocols have been introduced. Clinical practice has changed substantially, warranting new approaches and a comprehensive review and update of the evidence.
Material and methodsOnce again, we used the GRADE approach, supported by an electronic tool (https://gradepro.org). The clinical scenarios are the same as in the previous version (induction and maintenance in severe and mild-moderate flare-ups), as are the variables and their evaluation. However, in the updated guidelines, three questions have been deleted, 14 added and 30 maintained, making a total of 44 clinical questions. After an exhaustive review of the evidence, the recommendations are now updated.
ResultsOf the 44 questions analysed, no recommendation could be established in two due to the very low quality of the evidence, while in the other 42, based on different degrees of quality of evidence, recommendations were made according to the GRADE system. In 25 of these questions the final recommendation is strongly in favour, in six strongly against, in seven weakly in favour and in four weakly against. According to the scenarios and recommendations, six algorithms are proposed as a simple guide for practical decision-making.
ConclusionsThe aim of this update of the 2013 guidelines is to provide answers, based on the GRADE approach, to the different questions we ask ourselves daily when deciding the most appropriate treatment for our patients with ulcerative colitis in the different clinical scenarios.
Keywords:
Ulcerative colitis
Treatment
Salicylates
Corticosteroids
Immunosuppressors
Biological
GRADE
El Texto completo está disponible en PDF
Bibliografía
[1]
J.E. Lennard-Jonnes.
Classification of inflammatory bowel disease.
Scand J Gastroenterol, 170 (1989), pp. 2-6
[2]
M.S. Silverberg, J. Satsangi, T. Ahmad, I.D. Arnott, C.N. Bernstein, S.R. Brant, et al.
Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of gastroenterology.
Can J Gastroenterol., 19 Suppl A (2005), pp. 5-36
[3]
A.K. Azad Khan, D.T. Howes, J. Piris, S.C. Truelove.
Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
Gut., 21 (1980), pp. 232-240
[4]
B. Sicilia, R. Vicente, F. Gomollón.
Epidemiología de la enfermedad inflamatoria intestinal: controversias en la epidemiología clásica.
Acta Gastroenterol Latinoam., 39 (2009), pp. 135-145
[5]
G.R. Jones, M. Lyons, N. Plevris, P.W. Jenkinson, C. Bisset, C. Burgess, et al.
IBD prevalence in Lothian.
Scotland, derived by capture-recapture methodology. Gut., 68 (2019), pp. 1953-1960
[6]
GBD 2017 Inflammatory Bowel Disease Collaborators.
The global regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet Gastroenterol Hepatol, 5 (2020), pp. 17-30
[7]
Y. Wang, C.E. Parker, T. Bhanji, B.G. Feagan, J.K. MacDonald.
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev., 4 (2016), pp. CD000543
[8]
Y. Wang, C.E. Parker, B.G. Feagan, J.K. MacDonald.
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev., (2016 May 9), pp. CD000544
[9]
S.C. Truelove, L.J. Witts.
Cortisone in ulcerative colitis.
Final report on a therapeutic trial. BMJ., 2 (1955), pp. 1041-1048
[10]
C.A. Anderson, G. Boucher, C. Lees, A. Franke, M. D’Amato, K.D. Taylor, et al.
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
Nat Genet., 43 (2011), pp. 246-252
[11]
Gomollón F, Hinojosa J, Gassull MA editores. Enfermedad Inflamatoria Intestinal. IV edición. ERGON Mahadahonda Madrid. ISBN 978-84-17194-63-5.
[12]
Inflammatory bowel disease.,
[13]
J. Burgers, M. Smolders, T. van der Weidjen, D. Davis, R. Grol.
Clinical practice guidelines as a tool for improving patient care.
Improving patient care. The implementation of change in health care., 2nd Edition, pp. 91-110
[14]
F.L. Wolters, M.G. Russel, J. Sijbrandij, L.J. Schouten, S. Odes, L. Riis, et al.
Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study.
Scand J Gastroenterol Suppl., (2006), pp. 46-54
[15]
S. Odes, H. Vardi, M. Friger, F. Wolters, M.G. Russel, L. Riis, et al.
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.
Gastroenterology, 131 (2006), pp. 719-728
[16]
C.A. Lamb, N.A. Kennedy, T. Raine, P.A. Hendy, P.J. Smith, J.K. Limdi, et al.
British gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Gut., 68 (2019), pp. s1-s106
[17]
C.W. Ko, S. Singh, J.D. Feuerstein, C. Falck-Ytter, Y. Falck-Ytter, R.K. Cross, on behalf of the American Gastroenterological Association Institute Clinical Guidelines Committee AGA.
Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.
Gastroenterology, 156 (2019), pp. 748-764
[18]
D.T. Rubin, A.N. Ananthakrishnan, C.A. Siegel, B.G. Sauer, M.D. Long.
ACG clinical guideline: ulcerative colitis in adults.
Am J Gastroenterol., 114 (2019), pp. 384-413
[19]
C.N. Bernstein, A. Eliakim, S. Fedail, M. Fried, R. Gearry, K.L. Goh, et al.
World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015.
J Clin Gastroenterol., 50 (2016), pp. 803-818
[20]
C.J. Ooi, I. Hilmi, R. Banerjee, S.W. Chuah, S.C. Ng, S.C. Wei, et al.
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
J Gastroenterol Hepatol., 34 (2019), pp. 1296-1315
[21]
F. Magro, P. Gionchetti, R. Eliakim, S. Ardizzone, A. Armuzzi, M. Barreiro-de Acosta, for the European Crohn's and Colitis Organisation [ECCO], et al.
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.
Journal of Crohn's and Colitis, (2017), pp. 649-670
[22]
M. Harbord, R. Eliakim, D. Bettenworth, K. Karmiris, K. Katsanos, U. Kopylov, for the European Crohn's and Colitis Organisation [ECCO].
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
Journal of Crohn's and Colitis, (2017), pp. 769-784
[23]
F. Gomollón, S. García-López, B. Sicilia, J.P. Gisbert, J. Hinojosa, Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa.
Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU.
Gastroenterol Hepatol., 36 (2013), pp. 104-114
[24]
D. Turner, F.M. Ruemmele, E. Orlanski-Meyer, A.M. Griffiths, J. Martín de Carpi, J.J. Bronsky, et al.
Management of Paediatric Ulcerative Colitis, Part 1. Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology.
Hepatology and Nutrition. JPGN, 67 (2018), pp. 257-291
[25]
D. Turner, F.M. Ruemmele, E. Orlanski-Meyer, A.M. Griffiths, J. Martín de Carpi, J.J. Bronsky, et al.
Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology.
Hepatology and Nutrition. JPGN, 67 (2018), pp. 292-310
[26]
J. Satsangi, M. Silverber, S. Vermeire, J.F. Colombel.
The Montreal classification of inflammatory bowel disease: controversies, consensus and implications.
Gut., 55 (2006), pp. 25-1118
[27]
G. D’Haens, W.J. Sandborn, B.G. Feagan, K. Geboes, S.B. Hanauer, E.J. Irvine, et al.
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
Gastroenterology., 132 (2007), pp. 763-786
[28]
D. Turner, C.H. Seow, G. Geenberg, A.M. Griffiths, M. Silverberg, A.H. Steinhart.
A systematic prospective comparison of noninvasive disease activity indexes in ulcerative colitis.
Clin Gastroenterol Hepatol., 7 (2009), pp. 101-188
[29]
K.W. Schroeder, W.J. Tremaine, D.M. Ilstrup.
Coated oral 5- aminosalicylic acid therapy for mildly to moderately active ulcerative colitis, a randomized study.
N Engl J Med., 317 (1987), pp. 1625-1629
[30]
M. Seo, M. Okada, T. Yao, M. Ueki, S. Arima, M. Okumura.
An index of disease activity in patients with ulcerative colitis.
Am J Gastroenterol., 87 (1992), pp. 971-976
[31]
S. Lichtiger, D.H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, et al.
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
N Engl J Med., 330 (1994), pp. 1841-1845
[32]
R.S. Walmsley, R.C.S. Ayres, R.E. Pounder, R.N. Allan.
A simple clinical colitis activity index.
Gut., 43 (1998), pp. 29-32
[33]
D. Turner, A.R. Otley, D. Mack, J. Hyams, J. de Bruijne, K. Uusoue, et al.
Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.
Gastroenterology., 133 (2007), pp. 423-432
[34]
The GRADE Working Group.
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches.
BMC Health Serv Res., 4 (2004), pp. 38
[35]
D. Turner, C.M. Walsh, A.H. Steinhart, A.M. Griffiths.
Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.
Clin Gastroenterol Hepatol., 5 (2007), pp. 103-110
[36]
F. Bossa, S. Fiorella, N. Caruso, L. Accadia, G. Napolitano, M.R. Valvano, et al.
Continuous infusion versus bolus adminis- tration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial.
Am J Gastroenterol., 102 (2007), pp. 601-608
[37]
O. Shibolet, E. Regushevskaya, M. Brezis, K. Soares-Weiser.
Cyclosporine A for induction of remission in severe ulcerative colitis.
Cochrane Database Syst Rev., (2005), pp. CD004277
[38]
G. D’Haens, L. Lemmens, K. Geboes, L. Vandeputte, F. Van Acker, L. Mortelmans, et al.
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.
Gastroenterology., 120 (2001), pp. 1323-1329
[39]
S. García-López, F. Gomollón García, J. Pérez-Gisbert.
Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review.
Gastroenterol Hepatol., 28 (2005), pp. 607-614
[40]
G. Van Assche, G. D’Haens, M. Noman, S. Vermeire, M. Hiele, K. Asnong, et al.
Randomized, double blind comparison of 4mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis.
Gastroenterology, 125 (2003), pp. 1025-1031
[41]
F. Svanoni, U. Bonassi, F. Bagnolo, et al.
Effectiveness of cyclosporin A (CsA) in the treatment of active refractory ulcerative colitis (UC).
Gastroenterology, 114 (1998), pp. 1096
[42]
W. Cacheaux, P. Seksik, M. Lémann, P. Marteau, I. Nion-Larmurier, P. Afchain, et al.
Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis.
Am J Gastroenterol., 103 (2008), pp. 637-642
[43]
D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik, J. Filippi, et al.
Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Cidosporine versus infliximab in acute severe colitis refractory to intravenous steroids: a randomized study. Lancet, 380 (2012), pp. 1909-1915
[44]
J.G. Williams, M.F. Alam, L. Alrubaiy, I. Arnott, C. Clement, D. Cohen, et al.
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
Lancet Gastroenterol Hepatol, 1 (2016), pp. 15-24
[45]
R.D. Cohen, R. Stein, S.B. Hanauer.
Intravenous cyclosporin in ulcerative colitis: a five-year experience.
Am J Gastroenterol, 94 (1999), pp. 1587-1592
[46]
D.N. Moskovitz, G. Van Assche, B. Maenhout, J. Arts, M. Ferrante, S. Vermeire, et al.
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.
Clinical Gastroenterology and Hepatology, 4 (2006), pp. 760-765
[47]
S. Campbell, S. Travis, D. Jewell.
Ciclosporin use in acute ulcerative colitis: a long-term experience.
European Journal of Gastroenterology and Hepatology, 17 (2005), pp. 79-84
[48]
A.S. Cheifetz, J. Stern Bonassi, F. Bagnolo, et al.
Effectiveness of cyclosporin A (CsA) in the treatment of active refractory ulcerative colitis (UC).
Gastroenterology, 114 (1998), pp. 1096
[42]
W. Cacheaux, P. Seksik, M. Lémann, P. Marteau, I. Nion-Larmurier, P. Afchain, et al.
Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis.
Am J Gastroenterol., 103 (2008), pp. 637-642
[43]
D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik, J. Filippi, et al.
Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Cidosporine versus infliximab in acute severe colitis refractory to intravenous steroids: a randomized study. Lancet, 380 (2012), pp. 1909-1915
[44]
J.G. Williams, M.F. Alam, L. Alrubaiy, I. Arnott, C. Clement, D. Cohen, et al.
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
Lancet Gastroenterol Hepatol, 1 (2016), pp. 15-24
[45]
R.D. Cohen, R. Stein, S.B. Hanauer.
Intravenous cyclosporin in ulcerative colitis: a five-year experience.
Am J Gastroenterol, 94 (1999), pp. 1587-1592
[46]
D.N. Moskovitz, G. Van Assche, B. Maenhout, J. Arts, M. Ferrante, S. Vermeire, et al.
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.
Clinical Gastroenterology and Hepatology, 4 (2006), pp. 760-765
[47]
S. Campbell, S. Travis, D. Jewell.
Ciclosporin use in acute ulcerative colitis: a long-term experience.
European Journal of Gastroenterology and Hepatology, 17 (2005), pp. 79-84
[48]
A.S. Cheifetz, J.S. Garud, et al.
Cyclosporine is safe and effective in patients with severe ulcerative colitis.
Journal of Clinical Gastroenterology, 45 (2011), pp. 107-112
[49]
I. Ordás, E. Domènech, M. Mañosa, V. García-Sánchez, E. Iglesias-Flores, M. Peñalva, et al.
Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute SevereUlcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.
Am J Gastroenterol., 112 (2017), pp. 1709-1718
[50]
A. Kornbluth, D.H. Present, S. Lichtiger, S. Hanauer.
Cyclosporine for severe ulcerative colitis.
An user's guide. Am J Gastroenterol., 92 (1997), pp. 1424-1428
[51]
H. Ogata, T. Matsui, M. Nakamura, M. Lida, M. Takazoe, Y. Suzuki, et al.
Remission-induction and steroid-sparing efficacy by oral tacrolimus (FK506) therapy against refractory ulcerative colitis.
Gut., 55 (2006), pp. 1255-1262
[52]
H. Ogata, J. Kato, F. Hirai, et al.
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
Inflammatory bowel diseases, 18 (2012), pp. 803-808
[53]
Y. Komaki, F. Komaki Kato, F. Hirai, et al.
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
Inflammatory bowel diseases, 18 (2012), pp. 803-808
[53]
Y. Komaki, F.A. Ido, et al.
Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.
Journal of Crohn's & colitis, 10 (2016), pp. 484-494
[54]
M.M. Lawson, A.G. Thomas, A.K. Akobeng.
Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev., 19 (2006), pp. CD005112
[55]
J.P. Gisbert, Y. González-Lama, J. Maté.
Systematic review: infliximab therapy in ulcerative colitis.
Aliment Pharmacology Ther., 25 (2007), pp. 19-37
[56]
P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, J. Johanns, et al.
Infliximab for induction and maintenance therapy for ulcerative colitis.
N Engl J Med., 353 (2005), pp. 2462-2476
[57]
G. Jarnerot, E. Hertervig, I. Friis-Liby, L. Blomquist, P. Kar- lén, C. Grännö, et al.
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomi- zed, placebo-controlled study.
Gastroenterology., 128 (2005), pp. 1805-1811
[58]
C.S. Probert, S.D. Hearing, S. Schreiber, T. Kühbacher, S. Ghosh, I. Arnott, et al.
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.
Gut., 52 (2003), pp. 998-1002
[59]
A. Gustavsson, G. Järnerot, E. Hertervig, I. Friis-Liby, L. Blomquist, P. Karlén, et al.
Clinical trial: colectomy after rescue therapy in ulcerative colitis-3 year follow-up of the Swedish- Danish controlled infliximab study.
Aliment Pharmacol Ther., 32 (2010), pp. 984-989
[60]
A. Armuzzi, B. De Pascalis, A. Lupascu, P. Fedeli, D. Leo, M.C. Mentella, et al.
Infliximab in the treatment of steroid-dependent ulcerative colitis.
Eur Rev Med Pharmacil Sci, 8 (2004), pp. 231-233
[61]
T. Ochsenkuhn, M. Sackmann, B. Goke.
Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study.
Eur J Gastroenterol Hepatol, 16 (2004), pp. 1167-1171
[62]
A. Oussalah, L. Evesque, D. Laharie, X. Boblin, G. Boschetti, S. Nancey, et al.
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.
Am J Gastroenterol., 105 (2010), pp. 2617-2625
[63]
I. Dotan, Y. Ron, H. Yanai, S. Becker, S. Fishman, L. Yahav, et al.
Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease.
Inflamm Bowel Dis., 20 (2014), pp. 2247-2259
[64]
J.F. Brandse, D. Mould, O. Smeekes, Y. Ashruf, S. Kuin, A. Strik, et al.
A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease.
Inflamm Bowel Dis., 23 (2017), pp. 650-660
[65]
D.J. Gibson, Z.S. Heetun, C.E. Redmond, K.S. Nanada, D. Keegan, K. Byrne, et al.
An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.
Clin Gastroenterol Hepatol., 13 (2015), pp. 330-335
[66]
H. Bar-Yoseph, N. Levhar, L. Selinger, U. Manor, M. Yavzori, O. Picard, et al.
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Aliment Pharmacol Ther, 47 (2018), pp. 2
[67]
L. Gonczi, Z. Vegh, P.A. Golovics, M. Rutka, K.B. Gecse, R. Bor, et al.
Prediction of short and medium-term efficacy of biosimilar infliximab therapy.
Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?. J Crohns Colitis., 11 (2017 Nov 12), pp. 697-705
[68]
T. Kobayashi, Y. Suzuki, S. Motoya, F. Hirai, H. Ogata, H. Ito, et al.
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis.
J Gastroenterol., 51 (2016), pp. 241-251
[69]
N. Narula, J.K. Marshall, J.F. Colombel, G.I. Leontiadis, J.G. Williams, Z. Muqtadir, et al.
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.
Am J Gastroenterol, 111 (2016), pp. 477-491
[70]
D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik, J. Filippi.
for the Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
Gut, 0 (2017), pp. 1-7
[71]
J.E. Ollech, S. Dwadasi, V. Rai, N. Peleg, I. Normatov, A. Israel, et al.
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis Aliment Pharmacol Ther., (2019 Dec 25),
[72]
R. Rahimi, S. Nikfar, A. Rezaie, M. Abdollahi.
A Meta-analysis of antibiotic therapy for active ulcerative colitis.
Dig Dis Sci., 52 (2007), pp. 2920-2925
[73]
T. Ohjusa, K. Kato, S. Terao, T. Chiba, K. Mabe, K. Murakami, et al.
Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled mulcenter trial.
Am J Gastroenterol., 105 (2010), pp. 1820-1829
[74]
K. Kato, T. Ohkusa, S. Terao, T. Chiba, K. Murakami, A. Yanaka, et al.
Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study.
Alimentary pharmacology & therapeutics, 39 (2014), pp. 949-956
[75]
J.T. Ross, M.A. Matthay, H.W. Harris.
Secondary peritonitis: principles of diagnosis and intervention.
BMJ, 361 (2018), pp. k1407
[76]
G. Van Assche, S. Vermeire, P. Rutgeerts.
Management of acute severe ulcerative colitis.
Gut., 60 (2011), pp. 130-133
[77]
G.C. Nguyen, J. San.
Rising prevalence of venous thromboembolis and its impact on mortality among hospitalized inflammatory bowel disease patients.
Am J Gastroenterol., 103 (2008), pp. 2272-2280
[78]
J.Y. Wang, J.P. Terdiman, E. Vittinghoff, T. Minichiello, M.G. Varma.
Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events.
World J Gastroenterol., 15 (2009), pp. 927-935
[79]
F. González-Huix, F. Fernández-Bañares, M. Esteve-Comas, A. Abad- Lacruz, E. Cabré, D. Acero, et al.
Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis.
Am J Gastroenterol., 88 (1993), pp. 227-232
[80]
G.T. Ho, C. Mowat, C.J. Goddard, J.M. Fennell, N.B. Shah, R.J. Prescott, et al.
Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.
Aliment Pharmacol Ther., 19 (2004), pp. 1079-1087
[81]
M. Mañosa, E. Cabré, E. García-Planella, I. Bernal, J. Gordillo, M. Esteve, et al.
Decision tree for early introduction of res- cue therapy in active ulcerative colitis treated with steroids.
Inflamm Bowel Dis., 17 (2011), pp. 2497-2502
[82]
E. Doménech, R. Vega, I. Ojanguren, A. Hernández, E. García-Planella, I. Bernal, et al.
Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy.
Inflamm Bowel Dis., 14 (2008), pp. 1373-1379
[83]
S.C. Truelove, C.P. Willoughby, E.G. Lee, M.G. Kettlewell.
Further experience in the treatment of severe attacks of ulcerative colitis.
Lancet., 2 (1978), pp. 1086-1088
[84]
J.L. Cabriada, I. Vera, E. Domènech, M. Barreiro-de Acosta, M. Esteve, J.P. Gisbert, J. Panés, F. Gomollón, Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease.
Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
Gastroenterol Hepatol, 36 (2013), pp. 127-146
[85]
M. Mañosa, A. López San Román, E. García-Planella, G. Bastida, J. Hinojosa, Y. González-Lama, et al.
Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis.
Digestion., 80 (2009), pp. 30-35
[86]
W.J. Sandborn, J. Regula, B.G. Feagan, E. Belousova, N. Jojic, M. Lukas, et al.
Delayed-release oral mesalamine 4.8g/day (800 mg Tablet) is effective for patients with moderately active ulcerative colitis.
Gastroenterology., 137 (2009), pp. 1934-1943
[87]
B.G. Feagan, J.K. MacDonald.
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
Inflammatory bowel diseases, 18 (2012), pp. 1785-1794
[88]
B. Flourie, H. Hagege, G. Tucat, D. Maetz, X. Hébuterne, J.P. Kuyvenhoven, et al.
Randomised clinical trial: once vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Alimentary pharmacology & therapeutics, 37 (2013), pp. 767-775
[89]
M.A. Kamm, W.J. Sandborn, M. Gassull, S. Schreiber, L. Jackowski, T. Butler, et al.
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Gastroenterology, 132 (2007), pp. 66-75
[90]
W. Kruis, G. Kiudelis, I. Racz, I.A. Gorelov, J. Pokrotnieks, M. Horynski, et al.
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Gut, 58 (2009), pp. 233-240
[91]
S. Katz, G.R. Lichtenstein, S.M.A. afdi.
5-ASA dose-response: maximizing efficacy and adherence.
Clin Gastroenterol Hepatol., 6 (2010), pp. 1-16
[92]
M. Regueiro, E.V. Loftus, A.H. Steinhart, R.D. Cohen.
Medical management of left side ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
Inflamm Bowel Dis., 12 (2006), pp. 979-994
[93]
R. Bergman.
Parkes systematic review: the use of mesalazine in inflammatory bowel disease.
Aliment Pharmacol Ther., 23 (2006), pp. 841-855
[94]
J. Gisbert, F. Gomollón, J. Maté, J.M. Pajares.
Role of 5-Aminosalicylic Acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review.
Dig Dis Sci., 47 (2002), pp. 471-488
[95]
M. Safdi, C. Sninsky, P. Banks, L. Wruble, J. Deren, G. Koval, et al.
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
Am J Gastroenterol., 92 (1997), pp. 1867-1871
[96]
M. Vecchi, G. Meucci, P. Gionchetti, M. Beltrami, P. di Maurizio, L. Beretta, et al.
Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Aliment Pharmacol Ther., 15 (2001), pp. 251-256
[97]
P. Marteau, C.S. Probert, S. Lindgren, M.A. Gassull, T.G. Tan, A. Dignass, et al.
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Gut., 54 (2005), pp. 960-965
[98]
J. Marshall, J. Irvine.
Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Am J Gastroenterol., 95 (2000), pp. 1628-1636
[99]
J. Pokrotnieks, K. Marlicz, L. Paradowski, B. Margus, P. Zabo- rowski, R. Greinwald.
Efficacy and tolerability of mesalazine foam enema (Salofal foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
Aliment Pharmacol Ther., 14 (2000), pp. 1191-1198
[100]
S. Hanauer.
Dose-ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentre placebo-controlled trial.
Inflamm Bowel Dis., 4 (1998), pp. 79-83
[101]
P. Gionchetti, F. Rizzello, A. Venturi, M. Ferretti, C. Brignola, M. Miglioli, et al.
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
Dis Col Rectum., 41 (1998), pp. 93-97
[102]
C. Prantera, A. Viscido, L. Biancone, A. Francavilla, L. Giglio, M. Campieri.
A new oral delivery system for 5-ASA: preliminary clinical findings for MMX.
Inflamm Bowel Dis., 11 (2005), pp. 421-427
[103]
F. Manguso, R. Bennato, G. Lombardi, E. Riccio, G. Costantino, W. Fries, et al.
Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.
PLoS One., 11 (2016),
[104]
F. Rizzello, P. Gionchetti, R. Galeazzi, G. Novelli, D. Valpiani, A. D’ Arienzo, et al.
Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study.
Adv Ther., 18 (2001), pp. 261-271
[105]
F. Rizzello, P. Gionchetti, A. D’Arienzo, F. Manguso, G. di Matteo, V. Annese, et al.
Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a double blind placebo-controlled study.
Aliment Pharmacol Ther., 16 (2002), pp. 1109-1116
[106]
M. Campieri, S. Adamo, D. Valpiani, A. D’Arienzo, G. D’Albasio, M. Pitzalis, et al.
Oral beclomethasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study.
Aliment Pharmacol Ther., 17 (2003), pp. 1471-1480
[107]
Multicentre, double blind randomised, balanced parallel group.
controlled, dose range finding study of 5 mg every 2 days, 5 mg, and 10 mg of Beclometasone Dipropionate enteric coated tablets versus placebo in mild to moderate extensive ulcerative colitis patients under oral aminosalicylates (like mesalazine, sulfasalazine) preventive therapy.
Clinical Study Report no. RA/PR/1405/001/00. Chiesi Farmaceutici S.A. Data on file, (2003),
[108]
G. Van Assche, F. Manguso, M. Zibellini, J.L. Cabriada Nuño, A. Goldis, E. Tkachenko, et al.
Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study.
Am J Gastroenterol, 110 (2015), pp. 708-715
[109]
M.E. Sherlock, J.K. MacDonald, A.M. Griffiths, A.H. Steinhart, C.H. Seow.
Oral budesonide for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev., 10 (2015), pp. CD007698
[110]
W.J. Sandborn, S. Travis, L. Moro, R. Jones, T. Gautille, R. Bagin, et al.
Once-daily Budesonide MMX® extended- release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE 1 study.
Gastroenterology, 143 (2012), pp. 1218-1226
[111]
S. Travis, S. Danese, L. Kupcinskas, O. Alexeeva, G. D’Haens, P.R. Gibson, et al.
Once-daily budesonide MMX in active mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Gut, 63 (2014), pp. 433-441
[112]
D. Rubin, R. Cohen, W. Sandborn, G. Lichtenstein, J. Axler, R.B. Riddell, et al.
udesonide MMX 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-asas.
Inflammatory Bowel Diseases, 20 (2014), pp. S1
[113]
G.R. D’Haens, Á. Kovács, P. Vergauwe, F. Nagy, T. Molnár, Y. Bouhnik, et al.
Clinical trial: Preliminary efficacy and safety study of a new budesonide-MMX® 9 mg extended- release tablets in patients with active left-sided ulcerative colitis.
Journal of Crohn's and Colitis, 4 (2010), pp. 153-160
[114]
R. Löfberg, Å. Danielsson, O. Suhr, Å. Nilsson, R. Schiöler, A. Nyberg, et al.
Oral budesonide versus prednisone in patients with active extensive and left-sided ulcerative colitis.
Gastroenterology, 110 (1996), pp. 1713-1718
[115]
V. Gross, I. Bunganic, E.A. Belousova, T.L. Mikhailova, L. Kupcinskas, G. Kiudelis, et al.
3g mesalazina granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double blind, double-dummy, randomized trial.
J Crohn's Colitis, 5 (2011), pp. 129-138
[116]
D.T. Rubin, R.D. Cohen, W.J. Sandborn, G.R. Lichtenstein, J. Axler, R.H. Riddell, et al.
Budesonide Multimatrix is efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Journal of Crohn's and Colitis, (2017), pp. 785-791
[117]
C. Papi, A. Aratari, A. Moretti, M. Mangone, G. Margagnoni, M. Koch, et al.
Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates.
Dig Dis Sci., 55 (2010), pp. 2002-2007
[118]
G. Watkinson.
Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: a controlled trial employing restricted sequential analysis.
BMJ, 2 (1958), pp. 1077-1082
[119]
J.E. Lennard Jones, J.H. Baron, A.M. Connel, F. Avery Jones.
A double blind controlled trial of prednisolone 21 phosphate suppositories in the treatment of idiopathic proctitis.
Gut, 3 (1962), pp. 207-210
[120]
A. Danielsson, R. Löfberg, T. Persson, L. Salde, R. Schiöer, O. Suhr, et al.
An steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis.
Scand J Gastroenterol., 27 (1992), pp. 9-12
[121]
S. Hanauer, M. Robinson, R. Pruitt, A.J. Lazenby, T. Persson, L.G. Nilsson, et al.
Budesonide enema for the treatment of active distal ulcerative colitis and proctitis: a dose-ranging study.
Gastroenterology., 115 (1998), pp. 525-532
[122]
J. Zeng, L. Lv, Z.C. Mei.
Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis.
Journal of Gastroenterology and Hepatology, 32 (2017), pp. 558-566
[123]
J.K. Marshall, E.J. Irvine.
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a metaanalisis.
Gut., 40 (1997), pp. 775-781
[124]
M. Campieri, M. Cottone, F. Miglio, M. Astegiano, A. D’Arienzo, F. Manguso, et al.
Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis.
Aliment Pharmacol Ther., 12 (1998), pp. 361-366
[125]
S. Bar-Meir, H.H. Fidder, M. Faszczyk, G. Bianchi-Porro, G.C. Stumiolo, O. Mickisch, International Budesonide Study Group, et al.
Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis.
Dis Colon Rectum., 46 (2003), pp. 929-936
[126]
A. Hammond, T. Andus, M. Gierend, K.W. Ecker, J. Scholmerich, H. Herfarth, on behaflof. German Budesonide Foam Study Group.
Controlled, open, randomized multicentre trial com- paring the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.
Hepatogastroen- terology., 51 (2004), pp. 1345-1349
[127]
F. Manguso, A. Balzano.
The efficacy of rectal beclomethasone dipropionate vs 5-aminosalicylic acid in mild to moderate distal ulcerative colitis.
Aliment Pharmacol Ther., 26 (2007), pp. 21-29
[128]
C.J. Mulder, P. Fockens, J.W. Meijer, H. van de Heide, E.H. Wiltink, G.N.J. Tytgat.
Beclometahsone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis.
Eur J Gastroenterol Hepatol., 8 (1996), pp. 549-553
[129]
J.P. Gisbert, P.M. Linares, A.G. McNicholl, J. Maté, F. Gomollón.
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerativa colitis.
Aliment Pharmacol Ther., 30 (2009), pp. 126-137
[130]
J.P. Gisbert, F. Gomollón, J. Maté, J.M. Pajares.
Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal.
Gastroenterol Hepatol., 25 (2002), pp. 401-415
[131]
R. Oren, N. Arber, S. Odes, M. Moshkowitz, D. Keter, I. Pomeranz, et al.
Methotrexate in chronic active UC: a double-blind, randomised, Israeli multicenter trial.
Gastroenterology, 110 (1996), pp. 1416-1421
[132]
F. Carbonnel, J.F. Colombel, J. Filippi, K.H. Katsanos, L. Peyrin-Biroulet, M. Allez, et al.
Methotrexate is not Superior to Placebo in Inducing Steroid-free Remission, but Induces Steroid-free Clinical Remission in a Larger Proportion of Patients with Ulcerative Colitis.
Gastroenterology., 150 (2016 Feb), pp. 380-388
[133]
H.H. Herfarth, M.T. Osterman, K.L. Isaacs, J.D. Lewis, B.E. Sands.
Efficacy of methotrexate in ulcerative colitis: failure or promise.
Inflamm Bowel Dis, 16 (2010), pp. 1421-1430
[134]
H. Herfarth, E.L. Barnes, J.F. Valentine, J. Hanson, P.D.R. Higgins, K.L. Isaacs.
Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Gastroenterology, 155 (2018), pp. 1098-1108
[135]
W.J. Sandborn, C. Su, B.E. Sands, G.R. D'Haens, S. Vermeire, S. Schreiber, S. Danese, et al.
Tofacitinib as induction and maintenance therapy for ulceratvie colitis.
N Engl J Med., 376 (2017 May 4), pp. 1723-1736
[136]
B.E. Sands, A. Armuzzi, J.K. Marshall, J.O. Lindsay, W.J. Sandborn, S. Danese, et al.
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open Aliment Pharmacol Ther., (2019),
[137]
J. Brynskov, L. Freund, O.O. Thomsen, C.B. Andersen, S.N. Rasmussen, V. Binder.
Treatment of refractory ulcerative colitis with cyclosporin enemas.
Lancet, 1 (1989), pp. 721-722
[138]
T. Ranzi, M.C. Campanini, P. Velio, F. Quarto di Palo, P. Bianchi.
Treatment of chronic proctosigmoiditis with cyclosporin enemas.
Lancet., 2 (1989), pp. 97
[139]
W.J. Sandborn, W.J. Tremaine, K.W. Schroeder, B.L. Steiner, K.P. Batts, G.M. Lawson.
Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis.
Am J Gastroenterol., 88 (1993), pp. 640-645
[140]
W.J. Sandborn, W.J. Tremaine, K.W. Schroeder, K.P. Batts, G.M. Lawson, B.L. Steiner, et al.
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis.
Gastroenterology., 106 (1994), pp. 1429-1435
[141]
I.C. Lawrance, A. Baird, D. Lightower, G. Radford-Smith, J.M. Andrews, S. Connor.
Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis.
Clin Gastroenterol Hepatol, 15 (2017 Aug), pp. 1248-1255
[142]
Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214-20. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009;15:193-8.
[143]
A. Armuzzi, B. de Pascalis, A. Lupascu, P. Fedeli, D. Leo, M.C. Mentella, et al.
Infliximab in the treatment of steroid-dependent ulcerative colitis.
Eur Rev Med Pharmacol Sci., 8 (2004), pp. 231-233
[144]
A. Armuzzi, D. Pugliese, S. Danese, G. Rizzo, C. Felice, M. Marzo, et al.
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.
Inflamm Bowel Dis, 19 (2013), pp. 1065-1072
[145]
A. Armuzzi, D. Pugliese, S. Danese, G. Rizzo, C. Felice, M. Marzo, et al.
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Inflamm Bowel Dis, 20 (2014), pp. 1368-1374
[146]
W. Reinisch, W.J. Sandborn, D.W. Hommes, G. D'Haens, S. Hanauer, S. Schreiber, et al.
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Gut, 60 (2011), pp. 780-787
[147]
W.J. Sandborn, G. van Assche, W. Reinisch, J.F. Colombel, G. D'Haens, D.C. Wolf, et al.
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology, 142 (2012), pp. 257-265
[148]
Y. Suzuki, S. Motoya, H. Hanai, T. Matsumoto, T. Hibi, A.M. Robinson, et al.
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
J Gastroenterol, 49 (2014), pp. 283-294
[149]
Z.M. Zhang, W. Li, X.L. Jiang.
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
Gut Liver, 10 (2016), pp. 262-274
[150]
L. Peyrin-Biroulet, C. Laclotte, X. Roblin, M.A. Bigard.
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
World J Gastroenterol., 13 (2007), pp. 2328-2332
[151]
M. Iborra, J. Pérez-Gisbert, M.M. Bosca-Watts, A. López-García, V. García-Sánchez, A. López-Sanromán, Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU), et al.
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Gastroenterol., 52 (2017), pp. 788-799
[152]
A. Tursi, W. Elisei, R. Faggiani, L. Allegretta, N.D. Valle, G. Forti, et al.
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers Medicine (Baltimore)., 97 (2018 Aug), pp. e11897
[153]
W.J. Sandborn, B.G. Feagan, C. Marano, H. Zhang, R. Strauss, J. Johanns, for the PURSUIT-SC Study Group, et al.
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology, 146 (2014), pp. 85-95
[154]
C.S. Probert, S. Sebastian, D.R. Gaya, P.J. Hamlin, G. Gillespie, A. Rose, et al.
Golimumab induction and maintenance for moderate-to-severe ulcerative colitis: results from the GO-COLITIS (Golimumab: a Phase 4 UK, open label, single arm study on its utilization and impact in ulcerative colitis).
BMJ open Gastroenterol, 5 (2018 Jul 7),
[155]
P. Bossuyt, F. Baert, F. D’Heygere, A. Nakad, C. Reenaers, F. Fontaine, et al.
Early mucosal healing predicts favorable outcomes in patients with moderate to severe ulcerative colitis treated with golimumab: data from the real-life BE-SMART cohort.
Inflamm Bowel Dis, 25 (2019 Jan 1), pp. 156-162
[156]
P. Olivera, S. Danese, L. Pouillon, S. Bonovas, L. Peyrin-Biroulet.
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.
Dig Liver dis, 51 (2019 Mar), pp. 327-333
[157]
Yu Jin, Yan Li, Lian-Jie Lin, Chang-Qing, Zheng.
Metaanalisis of the effectivenes and safety of Vedolizumab for Ulcerative colitis.
World J Gastroenterol, 21 (2015 May 28), pp. 6352-6360
[158]
B.G. Feagan, D.T. Rubin, S. Danese, S. Vermeire, B. Abhyankar, S. Sankoh, et al.
Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists.
Clin Gastroenterol Hepatol., 15 (2017), pp. 229-239
[159]
S. Schreiber, A. Dignass, L. Peyrin-Biroulet, G. Hather, D. Demuth, M. Mosli, et al.
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
J Gastroenterol, 53 (2018), pp. 1048-1064
[160]
B.E. Sands, L. Peyrin-Biroulet, E.V. Loftus Jr., S. Danese, J.F. Colombel, M. Törüner, Study Group, et al.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
N Engl J Med., 381 (2019 Sep 26), pp. 1215-1226
[161]
B.E. Sands, W.J. Sandborn, R. Panaccione, C.D. O’Brien, H. Zhang, J. Johanns, for the UNIFI Study Group, et al.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med, 381 (2019), pp. 1201-1214
[162]
B.E. Sands, W.J. Sandborn, F. Feagan, R. Löfberg, T. Hibi, L.M. Gustofson, and the the Adacolumn Study Group, et al.
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
Gastroenterology., 135 (2008), pp. 400-409
[163]
W. Kruis, P. Nguyen, J. Morgenstern.
Granulocyte/Monocyte Adsorptive Apheresis in Moderate to Severe Ulcerative Colitis – Effective or Not?.
Digestion., 92 (2015), pp. 39-44
[164]
G. Bresci, G. Parisi, A. Masón, F. Scatena, A. Capria.
Treatment of patients with acute ulcerative colitis: convencional corticos- teroid therapy (MP) versus granulocytapheresis (GMA): a pilot study.
Dig Liver Dis., 39 (2007), pp. 430-434
[165]
H. Hanai, F. Watanabe, M. Yamada, Y. Sato, K. Takeuchi, T. Ilda, et al.
Adsorptive granulocyte and monocyte apheresis ver- sus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis.
Digestion., 70 (2004), pp. 36-44
[166]
M. Eberhardson, P. Karlén, L. Linton, P. Jones, A. Lindberg, M.J. Kostalla, et al.
Randomized, double-blind, placebo-controlled trial of CCR9-targeted leukapheresis treatment of ulcerative colitis patients.
J Crohns Colitis., 11 (2017 May 1), pp. 534-542
[167]
E. Doménech, J. Panés, J. Hinojosa, V. Annese, F. Magro, G.C. Sturniolo, and the ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa, et al.
Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A randomized, multicentre, clinical trial.
J Crohns Colitis., 12 (2018 May 25), pp. 687-694
[168]
J.L. Cabriada, E. Doménech, N. Ibargoyen, V. Hernández, J. Clofent, D. Ginard, et al.
Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry.
J Gastroenterol, 47 (2012), pp. 359-365
[169]
A. Dignass, A. Akbar, A. Hart, S. Subramanian, G. Bommelaer, D.C. Baumgart, et al.
Safety and Ef cacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insuf cient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results.
Journal of Crohn's and Colitis, (2016), pp. 812-820
[170]
R. Sacco, A. Romano, A. Mazzoni, M. Bertini, G. Federici, S. Metrangolo, et al.
Granulocytapheresis in steroiddependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study.
J Crohns Colitis., 7 (2013), pp. e692-e697
[171]
Y. Yokoyama, M. Kawai, K. Fukunaga, K. Kamikozuru, K. Nagase, K. Nogami, et al.
Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA.
BMC Gastroenterol., 13 (2013), pp. 27
[172]
Y. Yokoyama, K. Matsuoka, T. Kobayashi, K. Sawada, T. Fujiyoshi, T. Ando, et al.
A large scale prospective, observacional study oof leuckcytapheresis for ulcerative colitis: tratment outcomes of 847 patients in clinical practice.
J Crohns Colitis., 8 (2014), pp. 981-991
[173]
A. Sakuraba, S. Motoya, K. Watanabe, M. Nishishita, K. Kante, T. Matsui, et al.
An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment.
Am J Gastroenterol, 104 (2009), pp. 2990-2995
[174]
Y. Shi, Y. Dong, W. Huang, D. Zhu, H. Mao, P. Su.
Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis PloS1, 11 (2016 Jun 13), pp. e0157259
[175]
S.P. Costello, W. Soo, R.V. Bryant, V. Jairath, J.M. Andrews.
Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis Aliment Pharmacol Ther., (2017), pp. 1-12
[176]
H. Fang, L. Fu, J. Wang.
Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Biomed Res Int, 2018 (2018 Sep 13), pp. 8941340
[177]
V. Jacob, C. Crawford, S. Cohen-Mekelburg, M. Viladomiu, G. Garbès Putzel, Y. Schneider, et al.
Single Delivery of High-diversity Fecal Microbiota Preparation by Colonoscopy is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.
Inflamm Bowel disease, 23 (2017 Jun), pp. 903-911
[178]
A. Uygun, K. Ozturk, H. Demirci, C. Oger, I.Y. Avci, T. Turker, et al.
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis Inflamm Bowel Dis., 23 (2017), pp. 903-911
[179]
Y. Derwa, D.J. Gracie, D.J. Hamlin, A.C. Ford.
Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
Aliment Pharmacol Ther., (2017), pp. 1-12
[180]
A. Sood, V. Midha, G.K. Makharia, V. Ahuja, D. Singal, P. Goswami, et al.
The probiotic preparation.
VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol., 7 (2009), pp. 1202-1209
[181]
L. Peyrin-Biroulet, W. Sandborn, B.E. Sands, W. Reinisch, W. Bemelman, R.V. Bryant, et al.
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Am J Gastroenterol, 110 (2015 Sep), pp. 1324-1338
[182]
R. Cohen, B.A. Woseth, R.A. Thisted, S.B. Hanauer.
Meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Am J Gastroenterol., 95 (2000), pp. 1263-1276
[183]
S. Hanauer, L.I. Good, M.W. Goodman, R.J. Pizinger, W.B. Strum, C. Lyss, et al.
Long-term use of mesalamine (Rowasa) suppo- sitories in remission maintenance of ulcerative proctitis.
Am J Gastroenterol., 95 (2000), pp. 1749-1754
[184]
W.L. Biddle, N.J. Greenberger, J.T. Swan, M.S. McPhee, P.B. Miner Jr..
5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.
Gastroenterology., 94 (1988), pp. 1075-1079
[185]
G. D’Albasio, P. Paoluzi, M. Campieri, G. Bianchi-Porro, A. Pera, L. Barbara.
Maintenance treatment of ulcerative proctitis with mesalazine suppositories: A double-blind placebo-controlled trial.
Am J Gastroenterol., 93 (1998), pp. 799-803
[186]
G. d'Albasio, F. Pacini, E. Camarri, A. Messori, G. Trallori, A.G. Bonanomi, et al.
Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
Am J Gastroenterol, 92 (1997), pp. 1143-1147
[187]
H. Yokoyama, S. Takagi, S. Kuriyama, S. Takahashi, H. Takahashi, M. Iwabuchi, et al.
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
Inflammatory Bowel Diseases, 13 (2007), pp. 1115-1120
[188]
J.P. Gisbert, P.M. Linares, A.G. McNicholl, J. Maté, F. Gomollón.
Meta- analysis: the efficacy of azathioprine and mercaptopurine in ulcerativa colitis.
Aliment Pharmacol Ther., 30 (2009), pp. 126-137
[189]
A. Timmer, P.H. Patton, N. Chande, J.W.D. McDonald, J.K. MacDonald.
Azathioprine and 6mercaptopurine for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev., (2016), pp. CD000478
[190]
S. Ardizzone, G. Maconi, A. Russo, V. Imbesi, E. Colombo, G. Bianchi Porro.
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.
Gut., 55 (2006), pp. 47-53
[191]
A. Cassinotti, G.C. Actis, P. Duca, A. Massari, E. Colombo, E. Gai, et al.
Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
Am J Gastroenterol., 104 (2009), pp. 2760-2767
[192]
E. Moreno-Rincon, J.M. Benitez, F.J. Serrano-Ruiz, et al.
Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal.
Inflamm Bowel Dis, 21 (2015), pp. 1564-1571
[193]
A.G. Fraser, T.R. Orchard, D.P. Jewell.
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
Gut., 50 (2002), pp. 485-489
[194]
Y. Wang, J.K. MacDonald, B. Vandermeer, A.M. Griffiths, W. El-Matary.
Metotrexate in maintenance of UC., (2015 Aug 11), pp. CD007560
[195]
N. Khan, A.M. Abbas, M. Moehlen, L. Balart.
Methotrexate in Ulcerative Colitis: A Nationwide Retrospective Cohort from the Veterans Affairs Health Care System.
Inflamm Bowel Dis, 19 (2013), pp. 1379-1383
[196]
M. Mañosa, V. García, L. Castro, O. García-Bosch, M. Chaparro, M. Barreiro-de Acosta, D. Carpio, M. Aguas.
Methotrexate in ulcerative colitis: A Spanish multicentric study on clinical use and efficacy JCC, 5 (2011), pp. 397-401
[197]
S. Saibeni, S. Bollani, A. Losco, A. Michielan, R. Sostegni, M. Devani.
The use of methotrexate for treatment of inflammatory bowel disease in clinical practice.
Digestive and Liver Disease, 44 (2012), pp. 123-127
[198]
A. Sakuraba, T. Sato, Y. Morohoshi, K. Matsuoka, S. Okamoto, N. Inoue.
Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis: A Pilot Study.
Ther Apher Dial., 16 (2012), pp. 213-218
[199]
W.J. Sandborn, P. Rutgeerts, B.G. Feagan, W. Reinisch, A. Olson, J. Johanns, et al.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Gastroenterology., 137 (2009), pp. 1250-1260
[200]
R. Panaccione, S. Ghosh, S. Middleton, J.R. Márquez, B.B. Scott, L. Flint, et al.
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Gastroenterology., 146 (2014), pp. 392-400
[201]
W.J. Sandborn, B.G. Feagan, C. Marano, H. Zhang, R. Strauss, J. Johanns, for the PURSUIT-SC Study Group, et al.
Subcutaneous Golimumab manteins Clinical Response in in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology, 146 (2014), pp. 96-109
[202]
P.R. Gibson, B.G. Feagan, W.J. Sandborn, C. Marano, R. Strauss, J. Johanns.
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year) Clin Transl Gastroenterol., 7 (2016 Apr 28), pp. e168
[203]
W. Reinisch, P.R. Gibson, W.J. Sandborn, B.G. Feagan, R. Strauss, J. Johanns, et al.
Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension J Crohns Colitis., 12 (2018 Aug 29), pp. 1053-1066
[204]
J. O’Connell, C. Rowan, R. Stack, G. Harkin, V. Parihar, G. Chan, et al.
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
Eur J Gastroenterol Hepatol, 30 (2018), pp. 1019-1026
[205]
C. Taxonera, C. Rodríguez, F. Bertoletti, L. Menchén, J. Arribas, M. Sierra, et al.
Clinical outcomes of golimumab as first, second or third Anti-TNF agent in patients with moderate-to-severe ulcerative colitis.
Inflamm Bowel Dis, 23 (2017), pp. 1394-1402
[206]
B.G. Feagan, P. Rutgeerts, B.E. Sands, S. Hanauer, J.F. Colombel, W.J. Sandborn, G. Van Assche, J. Axler, H.J. Kim, S. Danese, I. Fox, C. Milch, S. Sankoh, T. Wyant, J. Xu, A. Parikh.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
N Engl J Med, 369 (2013), pp. 699-710
[207]
B.G. Feagan, D.T. Rubin, S. Danese, S. Vermeire, B. Abhyankar, S. Sankoh, et al.
Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists.
Clin Gastroenterol Hepatol., 15 (2017), pp. 229-239
[208]
E. Loftus Jr., J.F. Colombel, B.G. Feagan, S. Vermeire, W.J. Sandborn, B.E. Sands, et al.
Long term efficacy of Vedolizumab for UC) Long term efficacy of Vedolizumab for UC JCC, 11 (2017 Apr 1), pp. 400-411
[209]
S. Schreiber, A. Dignass, L. Peyrin-Biroulet, G. Hather, D. Demuth, M. Mosli, et al.
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
J Gastroenterol, 53 (2018), pp. 1048-1064
[210]
P. Rolny, R. Sadik.
Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy.
Int J Colorectal Dis., 17 (2002), pp. 67-69
[211]
E. Doménech, E. García-Planella, I. Bernal, M. Rosinach, E. Cabré, L. Fluvià, et al.
Azathioprine without oral ciclosporine in the long-term maintenance of remission induced by intravenous ciclosporine in severe, steroid-refractory ulcerative colitis.
Aliment Pharmacol Ther., 16 (2002), pp. 2061-2065
[212]
S. Campbell, S. Travis, D. Jewell.
Cyclosporine use in acute ulcerative colitis: a long-term experience.
Eur J Gastroenterol Hepatol., 17 (2005), pp. 79-84
[213]
R.D. Cohen, R. Stein, S.B. Hanauer.
Intravenous cyclosporine in ulcerative colitis: a five-year experience.
Am J Gastroenterol., 94 (1999), pp. 1587-1592
[214]
D.N. Moskovitz, G. van Assche, B. Maenhout, J. Arts, M. Ferrante, S. Vermeire, et al.
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.
Clin Gastroenterol Hepatol., 4 (2006), pp. 760-765
[215]
S. Campbell, S. Gosh.
Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome.
Dig Liver Dis., 35 (2003), pp. 546-551
[216]
G.C. Actis, M. Fadda, E. David, A. Sapino.
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporine: a long-term retrospective cohort study.
BMC Gastroenterol., 7 (2007), pp. 13
[217]
D. Bojic, Z. Radojicic, M. Nedeljkovic-Protic, M. Al-Ali, D.P. Jewell, S.P. Travis.
Long-term outcome after admission for acute ulcerative colitis in Oxford.
Inflamm Bowel Dis., 15 (2009), pp. 823-828
[218]
G. Pellet, C. Stefanescu, F. Carbonnel, L. Peyrin-Biroulet, X. Roblin, C. Allimant, et al.
Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis.
Clin Gastroenterol Hepatol., 17 (2019), pp. 494-501
[219]
C. Castaño-Milla, M. Chaparro, J.P. Gisbert.
Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis.
Aliment Pharmacol Ther, 39 (2014), pp. 645-659
[220]
O. Olén, R. Erichsen, M.C. Sachs, L. Pedersen, J. Halfvarson, J. Askling, et al.
Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.
Lancet., 395 (2020 Jan 11), pp. 123-131
[221]
P.L. Luisi.
La vida emergente.
Tusquets, (2010),
[222]
D. Gilbert.
Stumbling on Happiness.
Vintage Books, (2005),
[223]
S.P.L. Travis, P.D.R. Higgins, T. Orchard, C.J. Van der Woude, R. Panaccione, A. Bitton, et al.
Review article: defining remission in ulcerative colitis.
Aliment Pharmacol Ther., 34 (2011), pp. 113-124
[224]
S. Ben-Horin, Y. Chowers.
Review article: loss of response to anti-TNF treatments in Crohn's disease.
Aliment Pharmacol Ther., 33 (2011), pp. 9
[225]
K. Karmiris, G. Paintaud, M. Noman, C. Magdelaine-Beuzelin, M. Ferrante, D. Degenne, et al.
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Gastroenterology., 137 (2009), pp. 5
[226]
R.L. West, Z. Zelinkova, G.J. Wolbink, E.J. Kuipers, P.C. Stokkers, C.J. van der Woude.
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
Aliment Pharmacol Ther., 28 (2008 Nov 1), pp. 1122-1126
[227]
N. Vande Casteele, J. Jeyarajah, V. Jairath, B.G. Feagan, W.J. Sandborn.
Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis.
Clin Gastroenterol Hepatol, 17 (2019), pp. 1814-1821
[228]
O.J. Adedokun, W.J. Sandborn, B.G. Feagan, P. Rutgeerts, Z. Xu, C.W. Marano, et al.
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Gastroenterology, 147 (2014), pp. 1296-1307
[229]
O.J. Adedokun, Z. Xu, C.W. Marano, R. Strauss, H. Zhang, J. Johanns.
Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies.
J Crohns Colitis, 11 (2017), pp. 35-46
[230]
K. Papamichael, T. Van Stappen, N. Vande Casteele, A. Gils, T. Billiet, S. Tops, et al.
Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis.
Clin Gastroenterol Hepatol, 14 (2016), pp. 543-549
[231]
C. Steenholdt, J. Brynskov, Thomsen OØ, L.K. Munck, J. Fallingborg, L.A. Christensen, et al.
Individualised therapy is more costeffective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial.
Gut, 63 (2014), pp. 919-927
[232]
I. Dotan, Y. Ron, H. Yanai, S. Becker, S. Fishman, L. Yahav, et al.
Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease.
Inflamm Bowel Dis., 20 (2014), pp. 2247-2259
[233]
J.F. Brandse, D. Mould, O. Smeekes, Y. Ashruf, S. Kuin, A. Strik, et al.
A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease.
Inflamm Bowel Dis., 23 (2017), pp. 650-660
[234]
K. Papamichael, K.A. Chachu, R.K. Vajravelu, B.P. Vaughn, J. Ni, M.T. Osterman, A.S. Cheifetz.
Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab.
Clin Gastroenterol Hepatol., 15 (2017), pp. 1580-1588
[235]
S.R. Fernandes, S. Bernardo, C. Simões, A.R. Gonçalves, A. Valente, C. Baldaia, et al.
Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease.
Inflamm Bowel Dis., (2019 Jun 27),
[236]
N. Vande Casteele, M. Ferrante, G. Van Assche, V. Ballet, G. Compernolle, K. Van Steen, et al.
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Gastroenterology, 148 (2015), pp. 1320-1329
Publique en
Gastroenterología y Hepatología
Gastroenterología y Hepatología sigue las recomendaciones para la preparación, presentación y publicación de trabajos académicos en revistas biomédicas
Opciones de artículo